Clinical studies
A Double-blind, Placebo-controlled, Randomized Trial of XP-828L (800mg) on the Quality of Life and Clinical Symptoms of Patients with Mild-to-Moderate Psoriasis
21 July 2008
The National Psoriasis Foundation in the United States estimates 90percent of patients with psoriasis, representing two percent of the general population, have mild-to-moderate disease.
1 Traditionally, topical treatments including coal tar, dithranol (anthralin), and corticosteroids have been the mainstay of treatment for mild-to-moderate disease and are more effective in short-term use.
2 The diversity of topical therapies and their disparate side effects complicate treatment planning. Topical agents are also time consuming and unpleasant to use, potentially affecting compliance and compromising treatment efficacy. Furthermore, long-term use of topical agents is associated with significant side effects, including cutaneous atrophy, striae, and telangiectasia.
3 Although the effectiveness of topical agents to attenuate physical symptoms of psoriasis has been established, the inconvenience associated with their use often negatively impacts quality of life and reduces treatment compliance.
The complete article may be found in pdf format below.
psoriasis13-2.pdf
